Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07310420
What this trial is testing

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

Who this might be right for
Advanced Breast CancerEarly Breast Cancer
TerSera Therapeutics LLC 176
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Testing effectiveness (Phase 2)Looking for participantsNCT07180160
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Wenjin Yin 123
Testing effectiveness (Phase 2)Active Not RecruitingNCT05252988
What this trial is testing

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

Who this might be right for
Early-stage Breast CancerHER2 Positive Breast CancerHormone Receptor Positive
Spanish Breast Cancer Research Group 177
Testing effectiveness (Phase 2)UnknownNCT05808582
What this trial is testing

Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

Who this might be right for
Hormone Receptor-positive Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 60
Not applicableStudy completedNCT06086340
What this trial is testing

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Who this might be right for
Breast Cancer
Pfizer 779
Testing effectiveness (Phase 2)UnknownNCT04034589
What this trial is testing

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Testing effectiveness (Phase 2)Study completedNCT06465368
What this trial is testing

Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

Who this might be right for
Breast Cancer
Pfizer 121
Not applicableStudy completedNCT06311383
What this trial is testing

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 2,610
Testing effectiveness (Phase 2)UnknownNCT05411380
What this trial is testing

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Who this might be right for
Breast Cancer
wang shusen 73
Large-scale testing (Phase 3)Ended earlyNCT01633060
What this trial is testing

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 432
Large-scale testing (Phase 3)Active Not RecruitingNCT02513394
What this trial is testing

PALbociclib CoLlaborative Adjuvant Study

Who this might be right for
Breast Cancer
Alliance Foundation Trials, LLC. 5,796
Not applicableStudy completedNCT05478590
What this trial is testing

Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

Who this might be right for
Breast Neoplasms
Pfizer 440
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06254066
What this trial is testing

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Who this might be right for
Female Breast Cancer PatientsHistopathologically Confirmed Advanced HR +/HER2-invasive Breast CancerHRD Positive Advanced Breast Cancer
Zhejiang Cancer Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT06671262
What this trial is testing

Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer

Who this might be right for
Breast Adenocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 74
Early research (Phase 1)Active Not RecruitingNCT05266105
What this trial is testing

Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Olema Pharmaceuticals, Inc. 60
Not applicableLooking for participantsNCT06734533
What this trial is testing

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Who this might be right for
HR+ Breast Cancer
Hunan Cancer Hospital 80
Large-scale testing (Phase 3)UnknownNCT04337658
What this trial is testing

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 493
Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Large-scale testing (Phase 3)Looking for participantsNCT05851014
What this trial is testing

GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Genor Biopharma Co., Ltd. 350
Next Page